Company Active LTD

Company profile

Acu-Flow Limited

UK company SC624449, incorporated on 14 March 2019.

Home - Nebuflow

Nebu~Flow Transforming Respiratory Drug Delivery. Developing the next generation of nebulisers enabling delivery of life changing treatments.

Company number
SC624449
Incorporated
14 Mar 2019
Companies House status
Active

Company identity

Founded / incorporated
14 March 2019

Company number SC624449

Verify at Companies House
Legal name
ACU-FLOW LIMITED
Company type
LTD
Region
Unknown
Registered address
Unknown
Insolvency history
No

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
15

Company events

Reference milestones and recent Companies House filing stream events.

1 event
14 Mar
2019

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2020
Funded years
2020, 2022, 2024
Age at first award
1 years

Projects

2024 Collaborative R&D Lead participant

Tuneable Nebuliser for Inhalation drug delivery

1 Apr 2024 to 31 Mar 2026

Awarded
£699,524
Total cost £999,320

Acu-Flow is unlocking the delivery of the next generation of inhaled drugs for patients with respiratory disorders. According to the World Health Organisation, respiratory diseases (e.g. asthma/chronic obstructive pulmonary disorders (COPD)) are the leading causes of death and disability in the world. In the UK, the British Lung Foundation estimates 1 in ...

2022 Collaborative R&D Lead participant

New Generation of Nebulisers for Precision Respiratory Drug Delivery

1 May 2022 to 30 Apr 2024

Awarded
£544,776
Total cost £778,251

Acu-Flow is developing a new nebuliser device to enable inhalation for precise and efficient delivery of medicines to the lungs. According to the World Health Organisation, respiratory diseases (e.g. asthma and chronic obstructive pulmonary disorders) are the leading causes of death and disability in the world. In the UK, the British Lung Foundation estim...

2020 Collaborative R&D Lead participant

New Generation of Nebulisers for Efficient Respiratory Drug Delivery

1 Oct 2020 to 31 Aug 2021

Awarded
£115,808
Total cost £144,760

Acu-Flow will develop a new, unique innovative functionality for its new nebuliser platform to enable inhalation delivery of liquid formulations for the precision delivery of medicines to the lungs. According to the World Health Organisation, respiratory diseases are known as the leading causes of death and disability in the world, with an estimated clini...

Product types

Collaborative R&D